Skip to main content
Fig. 5 | BMC Endocrine Disorders

Fig. 5

From: Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma

Fig. 5

TMB may not serve as a biomarker for predicting the efficacy of ICIs. A-E The effects of five immune checkpoints on ACC prognosis. F-J The expressive correlations between TMB and immune checkpoints. K The expressive differences of immune checkpoints between high- and low-TMB groups. L The difference in TIDE score between high- and low-TMB groups

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us